Merck stock trails market as 2025 guidance disappoints, largely due to China
Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year. Shares of the New Jersey-based maker of oncology best-seller Keytruda fell over 10% mid-session despite the company posting beats on the top and bottom lines in the fourth quarter.
Hosted on MSN18h
MRK Earnings: Weak 2025 Guidance Mangles Merck Stock TodayMerck stock was mangled on Tuesday after the company posted a 2025 EPS guidance well below Wall Street’s estimates.
Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company (MRK – Research Report), with a ...
Hosted on MSN22h
Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock DropsGlobal pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results , with sales up 6.8% year on year to $15.62 billion ...
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
17hon MSN
MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...
Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback